Abstract Number: PB0891
Meeting: ISTH 2020 Congress
Theme: Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical
Background: Hemophilic arthropathy (HA) is a major cause of morbidity in hemophilia patients. Biochemical markers of joint tissue turnover are non-invasive, sensitive markers that might be useful for the early detection of HA. In contrast to imaging, they may reflect dynamic changes. Moreover, biomarkers with the capacity to predict long-term clinical outcomes have the potential to improve efficiency in clinical trials, especially nowadays with the numerous breakthroughs in the hemophilia treatment landscape. While there are many biomarker studies in osteoarthritis, there is less information readily available for HA.
Aims: To give an overview about the state-of-the-art of biochemical marker research in HA and create a solid basis for future research.
Methods: A systematic search in PubMed/EMBASE was performed on September 9, 2019. Studies published in English/Dutch were included when reporting about biochemical markers and HA. All publications (including abstracts from 2018/2019) were independently assessed by two researchers for eligibility.
Results: An initial 1307 publications were found. After strict analysis 20 publications were eligible for inclusion. The majority was cross-sectional in design (15 out 20), including relatively small numbers of patients (range 10-117) or focusing on differences in hemophilia patients versus healthy persons. Several studies consisted of biomarker research in tissues other than blood/urine (e.g. synovial biopsy) or studied biomarkers in animals. Fifteen studies correlated biochemical markers to radiographic joint damage or showed the change of these markers in reaction to hemarthroses. The most common markers studied are uCTX-II, sCOMP, sC1,2C, sCS846 and VEGF.
Conclusions: Although promising in theory, none of the investigated markers is currently sufficient for use in clinical practice/trials and not all type of markers studied are clinically feasible in HA. Clearly, larger longitudinal studies in well-defined populations should be designed to study the prognostic value of these markers for joint damage progression in an individual patient.
To cite this abstract in AMA style:
van Bergen EDP, van Vulpen LFD, Schutgens REG, Mastbergen SC, Lafeber FPJG. The Current State of Biochemical Marker Research in Hemophilic Arthropathy: A Review [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/the-current-state-of-biochemical-marker-research-in-hemophilic-arthropathy-a-review/. Accessed October 1, 2023.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/the-current-state-of-biochemical-marker-research-in-hemophilic-arthropathy-a-review/